Experiences in fragment-based drug discovery.

Fragment-based drug discovery (FBDD) has become established in both industry and academia as an alternative approach to high-throughput screening for the generation of chemical leads for drug targets. In FBDD, specialised detection methods are used to identify small chemical compounds (fragments) that bind to the drug target, and structural biology is usually employed to establish their binding mode and to facilitate their optimisation. In this article, we present three recent and successful case histories in FBDD. We then re-examine the key concepts and challenges of FBDD with particular emphasis on recent literature and our own experience from a substantial number of FBDD applications. Our opinion is that careful application of FBDD is living up to its promise of delivering high quality leads with good physical properties and that in future many drug molecules will be derived from fragment-based approaches.

[1]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[2]  James M. Woolven,et al.  Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. , 2012, Journal of medicinal chemistry.

[3]  S. Rabindran,et al.  Structure-based design of potent and selective 3-phosphoinositide-dependent kinase-1 (PDK1) inhibitors. , 2011, Journal of medicinal chemistry.

[4]  David S. Millan,et al.  Fragment based discovery of a novel and selective PI3 kinase inhibitor. , 2011, Bioorganic & medicinal chemistry letters.

[5]  Michael Czarniecki,et al.  Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel microM leads for the development of nM BACE-1 (beta-site APP cleaving enzyme 1) inhibitors. , 2010, Journal of medicinal chemistry.

[6]  Gianni Chessari,et al.  Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. , 2008, Journal of medicinal chemistry.

[7]  Marcel L Verdonk,et al.  Group Efficiency: A Guideline for Hits‐to‐Leads Chemistry , 2008, ChemMedChem.

[8]  Christopher W. Murray,et al.  Assessing the lipophilicity of fragments and early hits , 2011, J. Comput. Aided Mol. Des..

[9]  I. D. de Esch,et al.  Surface plasmon resonance biosensor based fragment screening using acetylcholine binding protein identifies ligand efficiency hot spots (LE hot spots) by deconstruction of nicotinic acetylcholine receptor α7 ligands. , 2010, Journal of medicinal chemistry.

[10]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[11]  W. Jencks,et al.  Entropic contributions to rate accelerations in enzymic and intramolecular reactions and the chelate effect. , 1971, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Hans Briem,et al.  A crystallographic fragment screen identifies cinnamic acid derivatives as starting points for potent Pim-1 inhibitors. , 2011, Acta crystallographica. Section D, Biological crystallography.

[13]  Gerhard Klebe,et al.  A small nonrule of 3 compatible fragment library provides high hit rate of endothiapepsin crystal structures with various fragment chemotypes. , 2011, Journal of medicinal chemistry.

[14]  David M. Wilson,et al.  Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. , 2012, Journal of medicinal chemistry.

[15]  Rob Leurs,et al.  Transforming fragments into candidates: small becomes big in medicinal chemistry. , 2009, Drug discovery today.

[16]  Gerhard Klebe,et al.  Fragment‐Based Lead Discovery: Screening and Optimizing Fragments for Thermolysin Inhibition , 2010, ChemMedChem.

[17]  Peter Brandt,et al.  Deconstruction of non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1 for exploration of the optimization landscape of fragments. , 2011, Journal of medicinal chemistry.

[18]  A. Tanner,et al.  Discovery and structure-activity relationship of 3-aminopyrid-2-ones as potent and selective interleukin-2 inducible T-cell kinase (Itk) inhibitors. , 2011, Journal of medicinal chemistry.

[19]  Rob Leurs,et al.  Fragment growing induces conformational changes in acetylcholine-binding protein: a structural and thermodynamic analysis. , 2011, Journal of the American Chemical Society.

[20]  R. Smits,et al.  Fragment library screening reveals remarkable similarities between the G protein-coupled receptor histamine H4 and the ion channel serotonin 5-HT3A , 2011, Bioorganic & medicinal chemistry letters.

[21]  Hans Matter,et al.  Fragment deconstruction of small, potent factor Xa inhibitors: exploring the superadditivity energetics of fragment linking in protein-ligand complexes. , 2012, Angewandte Chemie.

[22]  Qiyue Hu,et al.  Novel isoquinolone PDK1 inhibitors discovered through fragment-based lead discovery , 2011, J. Comput. Aided Mol. Des..

[23]  Gianni Chessari,et al.  Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. , 2010, Journal of medicinal chemistry.

[24]  A. Fersht,et al.  Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. , 2010, Chemistry & biology.

[25]  B. Davis,et al.  Structure-guided design of alpha-amino acid-derived Pin1 inhibitors. , 2009, Bioorganic & medicinal chemistry letters.

[26]  M. Drysdale,et al.  Medicinal chemistry of Hsp90 inhibitors. , 2008, Current topics in medicinal chemistry.

[27]  J. T. Metz,et al.  Ligand efficiency indices as guideposts for drug discovery. , 2005, Drug discovery today.

[28]  Mark Whittaker,et al.  Discovery of a Novel Hsp90 Inhibitor by Fragment Linking , 2010, ChemMedChem.

[29]  A. Good,et al.  The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[30]  James E Audia,et al.  Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor , 2011, The Journal of Neuroscience.

[31]  C. Murray,et al.  Potent, Selective Inhibitors of Fibroblast Growth Factor Receptor Define Fibroblast Growth Factor Dependence in Preclinical Cancer Models , 2011, Molecular Cancer Therapeutics.

[32]  W. Jahnke,et al.  Allosteric non-bisphosphonate FPPS inhibitors identified by fragment-based discovery. , 2010, Nature chemical biology.

[33]  Saul H Rosenberg,et al.  Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. , 2008, Journal of medicinal chemistry.

[34]  J. Praly,et al.  Binding evaluation of fragment-based scaffolds for probing allosteric enzymes. , 2012, Journal of medicinal chemistry.

[35]  Daniel A Erlanson,et al.  Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. , 2011, Bioorganic & medicinal chemistry letters.

[36]  James E. J. Mills,et al.  Design of a multi-purpose fragment screening library using molecular complexity and orthogonal diversity metrics , 2011, J. Comput. Aided Mol. Des..

[37]  Stuart L Schreiber,et al.  Organic synthesis toward small-molecule probes and drugs , 2011, Proceedings of the National Academy of Sciences.

[38]  Gianni Chessari,et al.  Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency. , 2010, Journal of medicinal chemistry.

[39]  M. Uesugi,et al.  [Discovering high-affinity ligands for proteins: SAR by NMR]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[40]  Christopher A Lepre,et al.  Practical aspects of NMR-based fragment screening. , 2011, Methods in enzymology.

[41]  Karl A. Walter,et al.  ChemInform Abstract: Discovery of Potent Nonpeptide Inhibitors of Stromelysin Using SAR by NMR. , 1997 .

[42]  Kam Y. J. Zhang,et al.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma , 2010, Nature.

[43]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[44]  Yuan Cheng,et al.  From fragment screening to in vivo efficacy: optimization of a series of 2-aminoquinolines as potent inhibitors of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1). , 2011, Journal of medicinal chemistry.

[45]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[46]  S. Barelier,et al.  Fragment-based deconstruction of Bcl-xL inhibitors. , 2010, Journal of medicinal chemistry.

[47]  Xiang Li,et al.  Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13. , 2011, Journal of medicinal chemistry.

[48]  A. Leach,et al.  Molecular complexity and fragment-based drug discovery: ten years on. , 2011, Current opinion in chemical biology.

[49]  C. Abell,et al.  A fragment-based approach to identifying ligands for riboswitches. , 2010, ACS chemical biology.

[50]  Warren R. J. D. Galloway,et al.  Drug discovery: A question of library design , 2011, Nature.

[51]  Doris Hafenbradl,et al.  A comparative study of fragment screening methods on the p38α kinase: new methods, new insights , 2011, J. Comput. Aided Mol. Des..

[52]  Kerim Babaoglu,et al.  Deconstructing fragment-based inhibitor discovery , 2006, Nature chemical biology.

[53]  S. Korsmeyer,et al.  An inhibitor of Bcl-2 family proteins induces regression of solid tumours , 2005, Nature.

[54]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[55]  Gianni Chessari,et al.  Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors. , 2006, Journal of medicinal chemistry.

[56]  Paul D. Leeson,et al.  The influence of the 'organizational factor' on compound quality in drug discovery , 2011, Nature Reviews Drug Discovery.

[57]  I. Kuntz,et al.  The maximal affinity of ligands. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[59]  C. Murray,et al.  The rise of fragment-based drug discovery. , 2009, Nature chemistry.

[60]  Claudio Luchinat,et al.  Entropic contribution to the linking coefficient in fragment based drug design: a case study. , 2010, Journal of medicinal chemistry.

[61]  Mladen Vinković,et al.  Fragment-based discovery of the pyrazol-4-yl urea (AT9283), a multitargeted kinase inhibitor with potent aurora kinase activity. , 2009, Journal of medicinal chemistry.

[62]  Paul Bamborough,et al.  Selectivity of kinase inhibitor fragments. , 2011, Journal of medicinal chemistry.

[63]  J. Mestan,et al.  Binding or bending: distinction of allosteric Abl kinase agonists from antagonists by an NMR-based conformational assay. , 2010, Journal of the American Chemical Society.

[64]  Marcel L Verdonk,et al.  Identification of inhibitors of protein kinase B using fragment-based lead discovery. , 2007, Journal of medicinal chemistry.

[65]  Lingyan Wang,et al.  Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. , 2010, Journal of medicinal chemistry.

[66]  T. Blundell,et al.  Structural biology in fragment-based drug design. , 2010, Current opinion in structural biology.

[67]  F. Giordanetto,et al.  Discovery of novel class 1 phosphatidylinositide 3-kinases (PI3K) fragment inhibitors through structure-based virtual screening. , 2011, Bioorganic & medicinal chemistry letters.

[68]  Andrew L Hopkins,et al.  Fragment screening by surface plasmon resonance. , 2010, ACS medicinal chemistry letters.

[69]  Denise G. Teotico,et al.  Docking for fragment inhibitors of AmpC β-lactamase , 2009, Proceedings of the National Academy of Sciences.

[70]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[71]  Gregg Siegal,et al.  Fragment screening of stabilized G-protein-coupled receptors using biophysical methods. , 2011, Methods in enzymology.

[72]  Anthony M Giannetti,et al.  From experimental design to validated hits a comprehensive walk-through of fragment lead identification using surface plasmon resonance. , 2011, Methods in enzymology.

[73]  Christopher W Murray,et al.  Identification of novel p38alpha MAP kinase inhibitors using fragment-based lead generation. , 2005, Journal of medicinal chemistry.

[74]  Ian Collins,et al.  Identification of 4-(4-aminopiperidin-1-yl)-7H-pyrrolo[2,3-d]pyrimidines as selective inhibitors of protein kinase B through fragment elaboration. , 2008, Journal of medicinal chemistry.

[75]  J. E. Elder,et al.  Fragment‐Based Screen against HIV Protease , 2010, Chemical biology & drug design.

[76]  J. Briand,et al.  Aminoindazole PDK1 Inhibitors: A Case Study in Fragment-Based Drug Discovery. , 2010, ACS medicinal chemistry letters.

[77]  Marcel L. Verdonk,et al.  The consequences of translational and rotational entropy lost by small molecules on binding to proteins , 2002, J. Comput. Aided Mol. Des..

[78]  Roy J. Vaz,et al.  Fragment screening of inhibitors for MIF tautomerase reveals a cryptic surface binding site. , 2010, Bioorganic & medicinal chemistry letters.

[79]  Gabriele Varani,et al.  A small-molecule probe induces a conformation in HIV TAR RNA capable of binding drug-like fragments. , 2011, Journal of molecular biology.

[80]  Zhijian Zhao,et al.  High concentration electrophysiology-based fragment screen: discovery of novel acid-sensing ion channel 3 (ASIC3) inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[81]  Peter Brandt,et al.  Identification of a novel scaffold for allosteric inhibition of wild type and drug resistant HIV-1 reverse transcriptase by fragment library screening. , 2011, Journal of medicinal chemistry.

[82]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[83]  Christopher W Murray,et al.  Fragment-based lead discovery: leads by design. , 2005, Drug discovery today.

[84]  R. Stevens,et al.  Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor. , 2011, Journal of medicinal chemistry.

[85]  B. Davis,et al.  Discovery of cell-active phenyl-imidazole Pin1 inhibitors by structure-guided fragment evolution. , 2011, Bioorganic & medicinal chemistry letters.

[86]  Chris Abell,et al.  Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase. , 2010, Journal of the American Chemical Society.

[87]  Renaldo Mendoza,et al.  Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. , 2010, Bioorganic & medicinal chemistry letters.

[88]  Gianni Chessari,et al.  Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency. , 2007, Journal of medicinal chemistry.

[89]  P. Clemons,et al.  Route to three-dimensional fragments using diversity-oriented synthesis , 2011, Proceedings of the National Academy of Sciences.

[90]  Hoan Vu,et al.  Fragment-based screening by X-ray crystallography, MS and isothermal titration calorimetry to identify PNMT (phenylethanolamine N-methyltransferase) inhibitors. , 2010, The Biochemical journal.

[91]  B. Shoichet,et al.  Molecular docking and ligand specificity in fragment-based inhibitor discovery. , 2009, Nature chemical biology.

[92]  A. Hopkins,et al.  Ligand efficiency: a useful metric for lead selection. , 2004, Drug discovery today.

[93]  Lorenz C. Blum,et al.  970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. , 2009, Journal of the American Chemical Society.